Sustained long-term remission with tyrosine kinase inhibitor therapy in treatment-refractory B-cell acute lymphoblastic leukemia harboring a RCSD1::ABL2 fusion gene

Mohammad Faizan Zahid; Radhika Kainthla

doi:10.1080/10428194.2023.2264428

Sustained long-term remission with tyrosine kinase inhibitor therapy in treatment-refractory B-cell acute lymphoblastic leukemia harboring a RCSD1::ABL2 fusion gene

Leuk Lymphoma. 2024 Jan;65(1):123-127. doi: 10.1080/10428194.2023.2264428. Epub 2024 Jan 10.

Authors

Mohammad Faizan Zahid^{1

2}, Radhika Kainthla^{1

2}

Affiliations

¹ Department of Internal Medicine, Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
² Malignant Hematology Clinic, Parkland Health and Hospital System, Dallas, TX, USA.

PMID: 37812134
DOI: 10.1080/10428194.2023.2264428

No abstract available

Keywords: Acute lymphoblastic leukemia; Philadelphia chromosome-like; RCSD1::ABL2 fusion gene; targetable kinase fusions; tyrosine kinase inhibitors.

MeSH terms

Fusion Proteins, bcr-abl / genetics
Humans
Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / therapy
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use
Tyrosine Kinase Inhibitors*

Substances

Tyrosine Kinase Inhibitors
Protein Kinase Inhibitors
Fusion Proteins, bcr-abl